Clinical Trial

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07345494
Lead Sponsor Ascendis Pharma A/S
Conditions Hypoparathyroidism
Enrollment 50 participants
Start Date 2026-02-18
Primary Completion 2036-01 (estimated)
Study Completion 2036-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-02